Rahul Lakhotia

10PUBLICATIONS
12CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersHaematological tumoursElectrical energy storage
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 04, 2026
A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.

Max J Gordon, Milos D Miljkovic, Paige Milhon

|Jun 16, 2025
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas.

Rahul Lakhotia, Christopher Melani, Stefania Pittaluga

|Feb 03, 2025
Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.

Rahul Lakhotia, Christopher Melani, Kieron Dunleavy

|Feb 10, 2022
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma.

Rahul Lakhotia, Christopher Melani, Kieron Dunleavy

|Aug 25, 2021
Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL.

Milos D Miljkovic, Christopher Melani, Stefania Pittaluga

|Feb 07, 2021
Circulating tumour DNA in B-cell lymphomas: current state and future prospects.

Rahul Lakhotia, Mark Roschewski

Pageof 2

Frequent Collaborators

7 joint publications

Christopher Melani

6 joint publications

Mark Roschewski

5 joint publications

Stefania Pittaluga

4 joint publications

Elaine S Jaffe